2848 Organometallics, Vol. 29, No. 13, 2010
Zhang et al.
templates and olefinic compounds. Work is still in progress
following this pursuit.
and [Cp*RhCl2]2 (123.6 mg, 0.2 mmol). IR (KBr): ν/cm-1 3448.1,
2916.9, 1569.7, 1507.8, 1347.5, 1188.4, 1026.1, 803.6, 727.8, 527.9,
504.1. H NMR (400 MHz, CDCl3): δ (ppm) 7.56 (d, 4H; CH,
1
oxamidato), 7.08 (d, 4H; CH, oxamidato), 2.33 (s, 6H; CH3,
oxamidato), 1.33 (s, 30H; Cp*). Anal. Calcd for C36H44N2Cl2O2Rh2:
C, 53.15; H, 5.45; N, 3.44. Found: C, 53.05; H, 5.42; N, 3.31.
Preparation of Tetranuclear Complexes. [Cp*4Ir4(μ-N,N0-dip-
henyloxamidato)2(μ-4,40-bpe)2](OTf)4 (3a). Two equivalents of
AgOTf (36 mg, 0.14 mmol) was added to a suspension of bi-
nuclear complex 1a (48 mg, 0.05 mmol) in CH3OH (15 mL) at
room temperature, and the mixture was stirred for 4 h, followed
by filtration. One equivalent of 4,40-bpe (9 mg, 0.05 mmol) was
added to the filtrate, and the mixture was stirred for 15 h before
being filtered. The solvent was removed and the residue was
extracted with CH2Cl2. Yellow powders were obtained after
evaporation of the solvent under reduced pressure, washed with
diethyl ether, and dried in vacuo. Yield: 52 mg, 75.7%. IR (KBr):
ν/cm-1 3494.1, 3061.2, 2921.3, 1605.1, 1578.4, 1488.6, 1451.2,
1345.8, 1260.1, 1156.8, 1030.2, 748.3, 638.6, 574.2, 517.8. 1H
NMR (400 Hz, CDCl3): δ (ppm) 8.14 (d, 8H; CH, Py-H), 7.89
(d, 8H; CH, Py-H), 7.65(m, 12H; CH, oxamidato (8H); HCdCH,
4,40-bpe (4H)), 7.40 (m, 12H; CH, oxamidato), 1.25 (s, 60H; Cp*).
Anal. Calcdfor C96H100N8F12S4O16Ir4: C, 41.98; H, 3.67;N, 4.08.
Found: C, 41.96 ; H, 4.06; N, 4.06.
[Cp*4Ir4(μ-N,N0-bis(4-methylphenyl)oxamidato)2(μ-4,40-bpe)2]-
(OTf)4 (3b). This complex (yellow, 62.4 mg, 89%) was obtained
from 1b (50 mg, 0.05 mmol), AgOTf (36 mg, 0.14 mmol), and
4,40-bpe (10 mg, 0.05 mmol) by a similar procedure to that des-
cribed for 3a. IR (KBr): ν/cm-1 3506.2, 2922.6, 1613.3, 1585.1,
1507.3, 1343.9, 1260.1, 1158.2, 1031.4, 839, 639.5, 515.3. 1H
NMR (400 Hz, CD3OD): δ (ppm) 8.12 (d, 8H; CH, Py-H), 7.86
(d, 8H; CH, Py-H), 7.63 (s, 4H; HCdCH, 4,40-bpe), 7.46 (d, 8H;
CH, oxamidato), 7.25 (d, 8H; CH, oxamidato), 2.49 (s, 12H;
Experiment Section
All manipulations were performed using standard Schlenk
techniques under an atmosphere of nitrogen. CH2Cl2 was dried
over CaH2, and CH3OH was distilled over Mg/I2. THF, diethyl
ether, and hexane were dried over Na and then distilled under
1
nitrogen immediately prior to use. The H NMR spectra were
measured on a VAVCE-DMX 400 spectrometer in CDCl3 or
CD3OD. Elemental analysis was performed on an Elementar
Vario EL III analyzer. IR (KBr) spectra were recorded on a
Nicolet FT-IR spectrophotometer.
The oxamide compounds13 and [Cp*IrCl2]214 and [Cp*RhCl2]2
14
were prepared according to the reported procedures, while other
chemical reagents were purchased from commercial sources and
used without further purification.
Preparation of Binuclear Complexes. [Cp*2Ir2(μ-N,N0-diph-
enyloxamidato)Cl2] (1a). Two equivalents of n-BuLi (0.30 mL,
0.48 mmol) was added to a solution of N,N0-diphenyloxamide
(48 mg, 0.2 mmol) in 15 mL of THF at -78 °C. The reaction
mixture was allowed to reach room temperature gradually with
stirring in about 2 h. Then the mixture was added to a suspen-
sion of [Cp*IrCl2]2 (159.2 mg, 0.2 mmol) in 5 mL of THF and
stirred overnight at 50 °C. The solvent was evaporated in vacuo,
and the residue was extracted with CH2Cl2. The extract was
evaporated to dryness and washed with diethyl ether to give the
products (yellow, 148 mg, 76.8%). IR (KBr): ν/cm-1 3441.7,
2984.2, 2916, 1604.3, 1579.8, 1488.1, 1448.6, 1382.5, 1352,
1031.1, 944.6, 755.1, 697.8. 1H NMR (400 MHz, CDCl3):
δ (ppm) 7.60 (d, 4H; CH, oxamidato), 7.11-7.31 (m, 6H; CH,
oxamidato), 1.34 (s, 30H; Cp*). Anal. Calcd for C34H40N2-
Cl2O2Ir2: C, 42.36; H, 4.18; N, 2.91. Found: C, 42.03; H, 4.20;
N, 2.64.
CH3, oxamidato), 1.25 (s, 60H; Cp*). Anal. Calcd for C100H108
-
N8F12S4O16Ir4: C, 42.85; H, 3.88; N, 4.00. Found: C, 42.78; H,
4.06; N, 3.50.
[Cp*2Ir2(μ-N,N0-bis(4-methylphenyl)oxamidato)Cl2] (1b). This
complex (yellow, 150 mg, 75.6%) was prepared in a way analo-
gous to that for complex 1a using N,N0-bis(4-methylphenyl)-
oxamide (53.6 mg, 0.2 mmol), n-BuLi (0.30 mL, 0.48 mmol),
and [Cp*IrCl2]2 (159.2 mg, 0.2 mmol). IR (KBr): ν/cm-1 3458.2,
3024.4, 2989, 2914.6, 1586.3, 1507.4, 1449.7, 1382.7, 1352.4,
1190.6, 1032.4, 803.1, 729.7, 536.2. 1H NMR(400 MHz, CDCl3):
δ (ppm) 7.48 (d, 4H; CH, oxamidato), 7.07 (d, 4H; CH, oxa-
midato), 2.34 (s, 6H; CH3, oxamidato), 1.33 (s, 30H; Cp*). Anal.
CalcdforC36H44N2Cl2O2Ir2: C, 43.58; H, 4.47; N, 2.82. Found: C,
43.17; H, 4.58; N, 2.54.
[Cp*2Rh2(μ-N,N0-diphenyloxamidato)Cl2] (2a). Two equiva-
lents of n-BuLi (0.30 mL, 0.48 mmol) was added to a solution of
N,N0-diphenyloxamide (48 mg, 0.2 mmol) in 15 mL of THF at
-78 °C. The reaction mixture was allowed to reach room tem-
perature gradually with stirring in about 2 h. Then the mixture
was added to a suspension of [Cp*RhCl2]2 (123.6 mg, 0.2 mmol)
in 5 mL of THF and stirred overnight at 50 °C. The solvent was
evaporated in vacuo, and the residue was extracted with CH2Cl2.
The extract was evaporated to dryness and washed with diethyl
ether to give the products (orange, 115.6 mg, 73.6%). IR (KBr):
ν/cm-1 3445.8, 2914.3, 1599.4, 1576.4, 1487.2, 1350, 1076.3,
1026.4, 756.1, 698.9. 1H NMR (400 MHz, CDCl3): δ (ppm) 7.69
(d, 4H; CH, oxamidato), 7.10-7.32 (m, 6H; CH, oxami-
dato), 1.34 (s, 30H; Cp*). Anal. Calcd for C34H40N2Cl2O2Rh2:
C, 51.99; H, 5.13; N, 3.57. Found: C, 51.69; H, 5.49; N, 3.57.
[Cp*2Rh2(μ-N,N0-bis(4-methylphenyl)oxamidato)Cl2] (2b). This
complex (orange, 129.2 mg, 79.3%) was prepared in a way
analogous to that for complex 2a using N,N0-bis(4-methylphe-
nyl)oxamide (53.6 mg, 0.2 mmol), n-BuLi (0.30 mL, 0.48 mmol),
[Cp*4Rh4(μ-N,N0-diphenyloxamide)oxamidato)2(μ-4,40-bpe)2]-
(OTf)4 (4a). This complex (orange, 40 mg, 67%) was obtained
from 2a (40 mg, 0.05 mmol), AgOTf (36 mg, 0.14 mmol), and
4,40-bpe (10 mg, 0.05 mmol) by a similar procedure to that
described for 3a. IR (KBr): ν/cm-1: 3494.6, 3062.2, 2919.9,
1601.8, 1576.1, 1488.1, 1429.8, 1261.6, 1224.1, 1157.9, 1029.5,
750, 639.1, 567.2, 518.5. N. 1H NMR (400 Hz, CDCl3): δ (ppm)
8.04 (d, 8H; CH, Py-H), 7.80 (d, 8H; CH, Py-H), 7.66 (m, 8H;
CH, oxamidato), 7.55 (s, 4H; HCdCH, 4,40-bpe), 7.40 (m, 12H;
CH, oxamidato), 1.29 (s, 60H; Cp*). Anal. Calcd for
C96H100N8F12S4O16Rh4: C, 48.25; H, 4.22; N, 4.69. Found: C,
48.14; H, 4.42; N, 4.42.
[Cp*4Rh4(μ-N,N0-bis(4-methylphenyl)oxamide)2(μ-4,40-bpe)2]-
(OTf)4 (4b). This complex (orange, 46.5 mg, 76%) was obtained
from 2b (41 mg, 0.05 mmol), AgOTf (36 mg, 0.14 mmol), and
4,40-bpe (10 mg, 0.05 mmol) by a similar procedure to that
described for 3a. IR (KBr): ν/cm-1 3495.2, 2921.6, 1610.5,
1577.3, 1505.6, 1429.6, 1341.4, 1260.6, 1223.8, 1157.3, 1029.4,
837.9, 639, 512.8. 1H NMR (400 Hz, CDCl3): δ (ppm) 8.02 (d,
8H; CH, Py-H), 7.77 (d, 8H; CH, Py-H), 7.53 (s, 4H; HCdCH,
4,40-bpe), 7.43 (d, 8H; CH, oxamidato), 7.18 (d, 8H; CH,
oxamidato), 2.47 (s, 12H; CH3, oxamidato), 1.28 (s, 60H;
Cp*). Anal. Calcd for C100H108N8F12S4O16Rh4: C, 49.11; H,
4.45; N, 4.58. Found: C, 49.01; H, 4.65; N, 4.33.
UV Irradiation of 3a. A powdered sample of 3a was placed
between two glass slides and irradiated using a broad Hg lamp
(300 W) for approximately 40 h. Yellow crystals of 5a suitable
for X-ray diffraction study were obtained by slow diffusion of
diethyl ether into a concentrated solution of the complexes in
CH3OH. Conversion: 100% (rctt-tpcb: 64.5%; rtct-tpcb:
35.5%). 1H NMR (400 Hz, CDCl3): δ (ppm) rctt-tpcb: 8.86
(d, 2H; CH, Py-H), 8.66 (m, 2H; CH, Py-H), 8.52 (d, 2H; CH,
Py-H), 8.08 (m, 2H; CH, Py-H), 7.32 - 7.68 (m, 6H; CH, Py-H),
6.94 (m, 2H; CH, Py-H), 5.70, (d, 2H; CH, cyclobutane), 4.98,
(13) Stylianides, N.; Danopoulos, A. A.; Pugh, D.; Hancock, F.;
Zanotti-Gerosa, A. Organometallics 2007, 26, 5627–5635.
(14) White, C.; Yates, A.; Maitles, P. M. Inorg. Synth. 1992, 29, 228–
234.